Wallin, Åsa K.

Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia: A Meta-analysis

Jansen, W. J., Ossenkoppele, R., Knol, D. L., Tijms, B. M., Scheltens, P., Verhey, F. R. J., Visser, P. J., Aalten, P., Aarsland, D., Alcolea, D., et al. (2015) · JAMA

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 1,610

Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study

Visser, P. J., Verhey, F., Knol, D. L., Scheltens, P., Wahlund, L.-O., Freund-Levi, Y., Tsolaki, M., Minthon, L., Wallin, Å. K., Hampel, H., et al. (2009) · The Lancet Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 614

Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype

Vermunt, L., Sikkes, S. A. M., van den Hout, A., Handels, R., Bos, I., van der Flier, W. M., Kern, S., Ousset, P., Maruff, P., Skoog, I., et al. (2019) · Alzheimer's & Dementia

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 570

Prevalence and prognosis of Alzheimer’s disease at the mild cognitive impairment stage

Vos, S. J. B., Verhey, F., Frölich, L., Kornhuber, J., Wiltfang, J., Maier, W., Peters, O., Rüther, E., Nobili, F., Morbelli, S., et al. (2015) · Brain

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 383

Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum

Jansen, W. J., Janssen, O., Tijms, B. M., Vos, S. J. B., Ossenkoppele, R., Visser, P. J., Amyloid Biomarker Study Group, Aarsland, D., Alcolea, D., Altomare, D., et al. (2022) · JAMA Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 290

Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease

Mattsson, N., Groot, C., Jansen, W. J., Landau, S. M., Villemagne, V. L., Engelborghs, S., Mintun, M. M., Lleo, A., Molinuevo, J. L., Jagust, W. J., et al. (2018) · Alzheimer's & Dementia

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 88

Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting

Wallin, Å. K., Andreasen, N., Eriksson, S., Båtsman, S., Näsman, B., Ekdahl, A., Kilander, L., Grut, M., Rydén, M., Wallin, A., et al. (2007) · Dementia and Geriatric Cognitive Disorders

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 84

Mild versus moderate stages of Alzheimer’s disease: Three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy

Wattmo, C., Minthon, L., & Wallin, Å. K. (2016) · Alzheimer's Research & Therapy

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 83

Long-term outcome and prediction models of activities of daily living in Alzheimer disease with cholinesterase inhibitor treatment

Wattmo, C., Wallin, Å. K., Londos, E., & Minthon, L. (2011) · Alzheimer Disease & Associated Disorders

Dementia and Cognitive Impairment ResearchCholinesterase and Neurodegenerative Diseases

Cited by 52

Galantamine treatment in Alzheimer's disease: response and long-term outcome in a routine clinical setting

Wallin, Å., Minthon, & Wattmo, C. (2011) · Neuropsychiatric Disease and Treatment

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 50